Beximco Pharmaceuticals Limited
BXP.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | £26,136 | £17,184 | £25,872 | £23,102 |
| - Cash | £1,655 | £859 | £854 | £1,160 |
| + Debt | £6,193 | £2,093 | £4,894 | £7,428 |
| Enterprise Value | £30,674 | £18,418 | £29,912 | £29,370 |
| Revenue | £12,300 | £11,714 | £11,341 | £10,987 |
| % Growth | 5% | 3.3% | 3.2% | – |
| Gross Profit | £5,570 | £5,408 | £5,031 | £4,803 |
| % Margin | 45.3% | 46.2% | 44.4% | 43.7% |
| EBITDA | £2,607 | £2,953 | £2,261 | £2,386 |
| % Margin | 21.2% | 25.2% | 19.9% | 21.7% |
| Net Income | £1,830 | £1,681 | £1,479 | £1,365 |
| % Margin | 14.9% | 14.3% | 13% | 12.4% |
| EPS Diluted | 4.1 | 3.77 | 3.31 | 3.06 |
| % Growth | 8.8% | 13.9% | 8.2% | – |
| Operating Cash Flow | £1,038 | £1,697 | £1,766 | £2,131 |
| Capital Expenditures | -£1,317 | -£311 | -£621 | -£416 |
| Free Cash Flow | -£280 | £1,387 | £1,145 | £1,715 |